A step closer to drugging the p53 tumour suppressor pathway

At the recently held 11th International Congress on Targeted Anticancer Therapies (TAT) in Paris, K. Wiman from the Karolinska Institutet, Stockholm, Sweden, reported on findings from his more than a decade long research efforts on drugging the p53 pathway. Read more here.